Drug profile · INN
pegvaliase-pqpz
PALYNZIQ
pegvaliase-pqpz (PALYNZIQ) is a phenylalanine hydrolytic enzyme. Associated with BioMarin Pharmaceutical Australia Pty Ltd. Route of administration: injection. Current US regulatory status: approved.
Drug details — pegvaliase-pqpz
- US status
- approved
- Class
- —
- Route
- INJECTION
- Patents
- 0
- Programs
- 3
- Data quality
- 0.89
Quick answer
pegvaliase-pqpz (PALYNZIQ) is a phenylalanine hydrolytic enzyme. Associated with BioMarin Pharmaceutical Australia Pty Ltd. Route of administration: injection. Current US regulatory status: approved.
Key facts
Mechanism of action
Phenylalanine hydrolytic enzyme
Primary target: Phenylalanine
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is pegvaliase-pqpz?
pegvaliase-pqpz (PALYNZIQ) is a phenylalanine hydrolytic enzyme. Associated with BioMarin Pharmaceutical Australia Pty Ltd. Route of administration: injection. Current US regulatory status: approved.
What is the brand name for pegvaliase-pqpz?
PALYNZIQ is a marketed brand name for pegvaliase-pqpz. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of pegvaliase-pqpz?
pegvaliase-pqpz has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.